Editorial
Ascertainment Bias in Anaphylaxis Safety Data of COVID-19 Vaccines

https://doi.org/10.1016/j.jaip.2021.04.025Get rights and content

Cited by (0)

Conflict of interest: J. O’B. Hourihane and A. M. Byrne have provided advice, without remuneration, to Ireland's Health Products Regulatory Authority and National Immunisation Advisory Council. K. Blümchen has provided lectures and expert testimony for Novartis and Bencard Allergie; has provided lectures for HAL Allergy, ThermoFisher, Allergopharma, ALK, and Nutricia; has provided lectures and expert testimony and received institutional grants from DBV Technologies (France) and Aimmune Therapeutics (USA); and has provided expert testimony for Nestle. P. J. Turner has provided expertise to the UK MHRA without remuneration; and has an honorary contract with Public Health England. M. Greenhawt has served as a consultant for the Canadian Transportation Agency, ThermoFisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Acquestive, Allergy Therapeutics, Pfizer, US World Meds, Allergenis, Aravax, and Monsanto; is a member of the Scientific Advisory Council for the National Peanut Board; has received honorarium for lectures from ThermoFisher, Aimmune, DBV, Before Brands, multiple state allergy societies, the American College of Allergy, Asthma & Immunology, and the European Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. The views expressed in this publication are those of the authors and not necessarily those of any National Health Service, government department or agency, or arms' length bodies.

View Abstract